Sermorelin

DB00010ApprovedWithdrawnProtein Based Therapies

Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth...

Mechanism: Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.
Curator reviewed
Primary indication: For the treatment of dwarfism, prevention of HIV-induced weight lossCurator reviewed
Formula / weight: C₁₄₉H₂₄₆N₄₄O₄₂S · 3357.882 Da

Resolves to

Compound

UNII89243S03TECAS86168-78-7KEGGC08192

Clinical / RWD

RxNorm56188ATCH01AC04ATCV04CD03PharmGKBPA164749110

Targets

Q02643GHRHR

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Marketed productAcross 1 country and 1 labeller

2ATC codesIncluding every combination product, plus 16 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sermorelin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account